All In Biotech

NDA 050514 · Harrow Eye

Natacyn

Natamycin · Ophthalmic · Polyene Antimicrobial

Priority review

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Oct 30, 1978

Approved uses

1

Original approval plus efficacy supplements

Registered trials

14

10 Phase 3, 1 recruiting

FAERS reports

410

307 serious, 96 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2025.

INDICATIONS AND USAGE: NATACYN ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 30, 1978 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • NATACYN · NATAMYCIN 5% · SUSPENSION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Natamycin" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective117
  • condition aggravated100
  • off label use81
  • somnolence64
  • abdominal distension62
  • abdominal pain59
  • vomiting59
  • appendicitis58
  • appendicolith58
  • ascites58
  • hyponatraemia58
  • nausea58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20106
20126
20137
20142
201510
201613
201715
201818
201921
202023
202147
202249
202367
202454
202543
202628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Natacyn (Natamycin)

2024 spending

$970K

Beneficiaries

788

1,282 claims

Per beneficiary

$1,231

$49.88 per unit

View as table
YearSpending
2020$0
2021$74,340
2022$647,733
2023$766,662
2024$969,715

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 58 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.